Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Stellar Biotechnologies’ Exclusive License Agreement on Bayer Innovations/Stellar KLH Technology

Abstract:
Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to announce that it has acquired an exclusive, irrevocable, worldwide, sub-licensable and royalty-free license to the technology developed through a Collaborative Research Agreement between Stellar and Bayer Innovations (BIG).

Stellar Biotechnologies’ Exclusive License Agreement on Bayer Innovations/Stellar KLH Technology

Port Hueneme, CA | Posted on December 7th, 2010

The license includes a carve-out by BIG for use of the technology in its non-Hodgkin lymphoma (NHL) vaccine which is currently under development. Otherwise, the license leaves Stellar free to commercialize the technology, exclusively, in all other fields.

Stellar CEO, Frank Oakes said, "The technology developed through the collaboration with BIG represents a breakthrough in the production of highly characterized, immunogenically potent carrier proteins (ICPs), not only in terms of quality and purity, but also for cost management in the final drug product. The technology will be integrated into BIG's NHL vaccine platform, and commercialized broadly by Stellar for other vaccines and related products."

Stellar's CEO letter to shareholders, dated 11/24/10, has been posted:

www.stellarbiotechnologies.com/investors/shareholders/index.php?&content_id=54

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.

####

About Stellar Biotechnologies
Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) is a world leader in sustainable manufacturing of pharmaceutical grade immune carrier proteins (ICP), particularly with regard to the present most important pharmaceutical protein in this class, KLH (Keyhole Limpet Hemocyanin). This evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source.

For more information, please click here

Contacts:
Darrell Brookstein

Copyright © Stellar Biotechnologies

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Chains of nanogold – forged with atomic precision September 23rd, 2016

Tattoo therapy could ease chronic disease: Rice-made nanoparticles tested at Baylor College of Medicine may help control autoimmune diseases September 23rd, 2016

Nanotech Grants Options September 22nd, 2016

Coffee-infused foam removes lead from contaminated water September 21st, 2016

Nanomedicine

Tattoo therapy could ease chronic disease: Rice-made nanoparticles tested at Baylor College of Medicine may help control autoimmune diseases September 23rd, 2016

BBI Solutions launches innovative conjugate blocking technology that enhances signal intensity for lateral flow immunoassays September 20th, 2016

Iran to hold intl. school on application of nanomaterials in medicine September 20th, 2016

Graphene nanoribbons show promise for healing spinal injuries: Rice University scientists develop Texas-PEG to help knit severed, damaged spinal cords September 19th, 2016

Announcements

Chains of nanogold – forged with atomic precision September 23rd, 2016

Tattoo therapy could ease chronic disease: Rice-made nanoparticles tested at Baylor College of Medicine may help control autoimmune diseases September 23rd, 2016

Nanotech Grants Options September 22nd, 2016

Coffee-infused foam removes lead from contaminated water September 21st, 2016

Patents/IP/Tech Transfer/Licensing

NIST Patents Single-Photon Detector for Potential Encryption and Sensing Apps September 16th, 2016

For first time, carbon nanotube transistors outperform silicon September 8th, 2016

Industrial Nanotech, Inc. Provides Shareholder Update August 22nd, 2016

Starpharma initiates new DEP™ drug delivery program with AstraZeneca July 27th, 2016

Nanobiotechnology

Tattoo therapy could ease chronic disease: Rice-made nanoparticles tested at Baylor College of Medicine may help control autoimmune diseases September 23rd, 2016

BBI Solutions launches innovative conjugate blocking technology that enhances signal intensity for lateral flow immunoassays September 20th, 2016

Iran to hold intl. school on application of nanomaterials in medicine September 20th, 2016

Graphene nanoribbons show promise for healing spinal injuries: Rice University scientists develop Texas-PEG to help knit severed, damaged spinal cords September 19th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic